Idexx Laboratories ( (IDXX) ) has released its Q1 earnings. Here is a breakdown of the information Idexx Laboratories presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
IDEXX Laboratories, Inc., a leading innovator in pet healthcare, provides diagnostic and software solutions to veterinary practices worldwide, ensuring the health of pets, livestock, and water safety. In its first quarter report for 2025, IDEXX Laboratories announced a 4% increase in revenue, reaching $998 million, driven by growth in its Companion Animal Group and Water segments. The company’s earnings per share rose to $2.96, marking a 5% increase, supported by a 90 basis point expansion in gross margin. Notably, the launch of IDEXX Cancer Dx™ for early canine lymphoma detection highlights IDEXX’s commitment to innovation in veterinary diagnostics. The company adjusted its 2025 revenue guidance to reflect a positive foreign exchange impact, projecting revenue between $4,095 million and $4,210 million, with an EPS outlook of $11.93 to $12.43. IDEXX remains focused on advancing its growth strategy through innovation, with expectations of continued revenue and EPS growth driven by strong execution and market expansion.